<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37188996</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-1250</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Zeitschrift fur Rheumatologie</Title><ISOAbbreviation>Z Rheumatol</ISOAbbreviation></Journal><ArticleTitle>[Assessment tools for systemic lupus erythematosus].</ArticleTitle><Pagination><StartPage>361</StartPage><EndPage>367</EndPage><MedlinePgn>361-367</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00393-023-01359-w</ELocationID><Abstract><AbstractText>A systematic assessment is critical for taking advantage of the current options for optimizing systemic lupus erythematosus (SLE) management. Without regular SLE activity measurements, treat to target and remission are empty words, and the EULAR recommendations therefore insist on these assessments. They rely on activity scores, such as SLEDAI, ECLAM and BILAG or more recently, EasyBILAG and SLE-DAS. Assessment is completed by organ-specific measurement methods and the evaluation of damage. In the study setting the classification criteria and combined endpoints for clinical testing are crucial, as is measurement of the quality of life. This review article provides an overview of the current state of SLE assessments.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aringer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bereich Rheumatologie, Medizinische Klinik und Poliklinik III und Universit&#xe4;tsCentrum f&#xfc;r Autoimmun- und Rheumatische Erkrankungen (UCARE), Universit&#xe4;tsklinikum und medizinische Fakult&#xe4;t Carl Gustav Carus, TU Dresden, Fetscherstr.&#xa0;74, 01307, Dresden, Deutschland. martin.aringer@uniklinikum-dresden.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leuchten</LastName><ForeName>Nicolai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bereich Rheumatologie, Medizinische Klinik und Poliklinik III und Universit&#xe4;tsCentrum f&#xfc;r Autoimmun- und Rheumatische Erkrankungen (UCARE), Universit&#xe4;tsklinikum und medizinische Fakult&#xe4;t Carl Gustav Carus, TU Dresden, Fetscherstr.&#xa0;74, 01307, Dresden, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Assessment-Tools f&#xfc;r den systemischen Lupus erythematodes.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Rheumatol</MedlineTA><NlmUniqueID>0414162</NlmUniqueID><ISSNLinking>0340-1855</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Ein systematisches Assessment ist entscheidend, um die heutigen M&#xf6;glichkeiten eines optimalen SLE(systemischer Lupus erythematodes)-Managements zu n&#xfc;tzen. Ohne regelm&#xe4;&#xdf;ige Aktivit&#xe4;tsmessung sind Treat-to-Target und Remission leere Begriffe, und die Empfehlungen der EULAR (European League Against Rheumatism) bestehen deshalb auf diesen Messungen. Sie basieren auf Aktivit&#xe4;tsscores wie SLEDAI (Systemic Lupus Erythematosus Disease Activity Index), ECLAM (European Consensus Lupus Activity Measurement) und BILAG (British Isles Lupus Assessment Group) oder neuer EasyBILAG und SLE-DAS (Disease Activity Score). Dazu kommen organbezogene Messmethoden und die Evaluation des Schadens. Im Studiensetting sind die Klassifikationskriterien und kombinierte Endpunkte f&#xfc;r klinische Pr&#xfc;fungen entscheidend sowie die Messung der Lebensqualit&#xe4;t. Dieser Review-Artikel gibt einen &#xdc;berblick &#xfc;ber den aktuellen Stand des SLE-Assessments.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Damage</Keyword><Keyword MajorTopicYN="N">Disease activity</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Low disease activity</Keyword><Keyword MajorTopicYN="N">Remission</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37188996</ArticleId><ArticleId IdType="doi">10.1007/s00393-023-01359-w</ArticleId><ArticleId IdType="pii">10.1007/s00393-023-01359-w</ArticleId></ArticleIdList><ReferenceList><Title>Literatur</Title><Reference><Citation>Aringer&#xa0;M, Costenbader&#xa0;K, Daikh&#xa0;D et&#xa0;al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151&#x2013;1159</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer&#xa0;M, Costenbader&#xa0;K, Daikh&#xa0;D et&#xa0;al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71:1400&#x2013;1412</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId><ArticleId IdType="pmc">6827566</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma Z, Cervera R, Brinks R et al (2020) Associations among classification criteria items within systemic lupus erythematosus. Arthritis Care Res 72:1820&#x2013;1826</Citation></Reference><Reference><Citation>Tan&#xa0;EM, Cohen&#xa0;AS, Fries&#xa0;JF et&#xa0;al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271&#x2013;1277</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri&#xa0;M, Orbai&#xa0;AM, Alarcon&#xa0;GS et&#xa0;al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677&#x2013;2686</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId><ArticleId IdType="pmc">3409311</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi&#xa0;SK, Johnson&#xa0;SR, Boumpas&#xa0;D et&#xa0;al (2018) Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res 70:571&#x2013;581</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23317</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Brinks R, D&#xf6;rner T et al (2021) European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis 80:775&#x2013;781</Citation></Reference><Reference><Citation>Aringer&#xa0;M, Costenbader&#xa0;K, Johnson&#xa0;SR (2022) Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. Expert Rev Clin Immunol 18:135&#x2013;144</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2033617</ArticleId><ArticleId IdType="pubmed">35076341</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Smolen JS (2006) Systemic lupus erythematosus&#x2014;activity and outcome. ZRheumatol 65(2):103&#x2013;106, 108&#x2013;109</Citation></Reference><Reference><Citation>Gladman&#xa0;DD, Ibanez&#xa0;D, Urowitz&#xa0;MB (2002) Systemic lupus erythematosus disease activity index 2000. J&#xa0;Rheumatol 29:288&#x2013;291</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma&#xa0;Z, Gladman&#xa0;DD, Su&#xa0;J et al (2018) A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology 57:1370&#x2013;1376</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key103</ArticleId><ArticleId IdType="pubmed">29688532</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma&#xa0;Z, Gladman&#xa0;DD, Zandy&#xa0;M et&#xa0;al (2021) Identifying a&#xa0;response for the systemic lupus erythematosus disease activity 2000 glucocorticoid index. Arthritis Care Res 73:1243&#x2013;1249</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24261</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitali&#xa0;C, Bencivelli&#xa0;W, Isenberg&#xa0;DA et&#xa0;al (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10:541&#x2013;547</Citation><ArticleIdList><ArticleId IdType="pubmed">1458710</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg&#xa0;DA, Rahman&#xa0;A, Allen&#xa0;E et&#xa0;al (2005) BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group&#x2019;s disease activity index for patients with systemic lupus erythematosus. Rheumatology 44:902&#x2013;906</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh624</ArticleId><ArticleId IdType="pubmed">15814577</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter&#xa0;LM, Gordon&#xa0;C, Yee&#xa0;CS et al (2022) Easy-BILAG: a&#xa0;new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology 61:4006&#x2013;4015</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab883</ArticleId><ArticleId IdType="pubmed">35077529</ArticleId><ArticleId IdType="pmc">9536795</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus&#xa0;D, Matos&#xa0;A, Henriques&#xa0;C et al (2019) Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a&#xa0;new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis 78:365&#x2013;371</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214502</ArticleId><ArticleId IdType="pubmed">30626657</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri&#xa0;M, Buyon&#xa0;J, Kim&#xa0;M (1999) Classification and definition of major flares in SLE clinical trials. Lupus 8:685&#x2013;691</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399680411281</ArticleId><ArticleId IdType="pubmed">10568907</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven&#xa0;RF, Mosca&#xa0;M, Bertsias&#xa0;G et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958&#x2013;967</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis&#xa0;A, Kostopoulou&#xa0;M, Alunno&#xa0;A et&#xa0;al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736&#x2013;745</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn&#xa0;K, Lau&#xa0;CS, Navarra&#xa0;SV et&#xa0;al (2016) Definition and initial validation of a&#xa0;Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75:1615&#x2013;1621</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Assun&#xe7;&#xe3;o&#xa0;H, Jesus&#xa0;D, Larosa&#xa0;M et al (2022) Definition of low disease activity state based on the SLE-DAS: derivation and validation in a&#xa0;multicentre real-life cohort. Rheumatology 61:3309&#x2013;3316</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab895</ArticleId><ArticleId IdType="pubmed">34864894</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8(1):e000538. https://doi.org/10.1136/lupus-2021-000538</Citation></Reference><Reference><Citation>Furie&#xa0;RA, Petri&#xa0;MA, Wallace&#xa0;DJ et al (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61:1143&#x2013;1151</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24698</ArticleId><ArticleId IdType="pubmed">19714615</ArticleId><ArticleId IdType="pmc">2748175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace&#xa0;DJ, Kalunian&#xa0;K, Petri&#xa0;MA et al (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a&#xa0;phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73:183&#x2013;190</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202760</ArticleId><ArticleId IdType="pubmed">23313811</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau&#xa0;FA, Vasconcelos&#xa0;C, D&#x2019;cruz&#xa0;D et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934&#x2013;3940</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20666</ArticleId><ArticleId IdType="pubmed">15593207</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;era&#xa0;M, Cisternas&#xa0;MG, Smilek&#xa0;DE et al (2015) Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 67:1305&#x2013;1313</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39026</ArticleId><ArticleId IdType="pubmed">25605554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou&#xa0;F, Lauwerys&#xa0;BR, Dall&#x2019;era&#xa0;M et al (2015) A proteinuria cut-off level of 0.7&#x202f;g/day after 12&#xa0;months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2:e123</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2015-000123</ArticleId><ArticleId IdType="pubmed">26629352</ArticleId><ArticleId IdType="pmc">4654096</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie&#xa0;R, Rovin&#xa0;BH, Houssiau&#xa0;F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N&#xa0;Engl J Med 383:1117&#x2013;1128</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin&#xa0;BH, Teng&#xa0;YKO, Ginzler&#xa0;EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a&#xa0;double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070&#x2013;2080</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie RA, Bruce IN, Vital EM, Dall&#x2019;era M, Maho E, Pinneda L, Tummala R (2023) Efficacy of anifrolumab across organ domains in patients with moderate to severe SLE: post hoc analysis of pooled data from the TULIP&#x2011;1 and TULIP&#x2011;2 trials. Lancet Rheumatol 4:e282&#x2013;e292</Citation></Reference><Reference><Citation>Mahmoud K, Zayat AS, Yusof MYM et al (2021) Ultrasound to identify SLE patients with musculoskeletal symptoms who respond best to therapy: The USEFUL longitudinal multicentre study. Rheumatology Rheumatology (Oxford). 60(11):5194&#x2013;5204</Citation></Reference><Reference><Citation>Albrecht&#xa0;J, Taylor&#xa0;L, Berlin&#xa0;JA et&#xa0;al (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J&#xa0;Invest Dermatol 125:889&#x2013;894</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0022-202X.2005.23889.x</ArticleId><ArticleId IdType="pubmed">16297185</ArticleId><ArticleId IdType="pmc">3928016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn&#xa0;A, Meuth&#xa0;AM, Bein&#xa0;D et&#xa0;al (2010) Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a&#xa0;modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 163:83&#x2013;92</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2010.09799.x</ArticleId><ArticleId IdType="pubmed">20394621</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman&#xa0;DD, Goldsmith&#xa0;CH, Urowitz&#xa0;MB et&#xa0;al (2000) The systemic lupus international collaborating clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J&#xa0;Rheumatol 27:373&#x2013;376</Citation><ArticleIdList><ArticleId IdType="pubmed">10685799</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand V, Simon LS, Meara AS et al (2020) Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. Lupus Sci Med 7(1):e000373. https://doi.org/10.1136/lupus-2019-000373</Citation></Reference><Reference><Citation>Williams-Hall R, Berry P, Williamson N et al (2022) Generation of evidence supporting the content validity of SF-36, FACIT&#x2011;F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN). Lupus Sci Med 9(1):e000712. https://doi.org/10.1136/lupus-2022-000712</Citation></Reference><Reference><Citation>Mcelhone&#xa0;K, Castelino&#xa0;M, Abbott&#xa0;J et&#xa0;al (2010) The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J&#xa0;Rheumatol 37:2273&#x2013;2279</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.091277</ArticleId><ArticleId IdType="pubmed">20810500</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi&#xa0;Z, Gandrup&#xa0;J, Katz&#xa0;PP et al (2018) Patient-reported outcome measures for use in clinical trials of SLE: a&#xa0;review. Lupus Sci Med 5:e279</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000279</ArticleId><ArticleId IdType="pubmed">30167315</ArticleId><ArticleId IdType="pmc">6109821</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauernfeind&#xa0;B, Aringer&#xa0;M, Prodinger&#xa0;B et&#xa0;al (2009) Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: a patient Delphi exercise. Arthritis Rheum 61:21&#x2013;28</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24165</ArticleId><ArticleId IdType="pubmed">19116959</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuchten&#xa0;N, Bauernfeind&#xa0;B, Kuttner&#xa0;J et&#xa0;al (2014) Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a&#xa0;Delphi exercise of experts and a&#xa0;literature review. Arthritis Care Res 66:1895&#x2013;1904</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22372</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vollenhoven&#xa0;RF, Petri&#xa0;MA, Cervera&#xa0;R et&#xa0;al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71:1343&#x2013;1349</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2011-200937</ArticleId><ArticleId IdType="pubmed">22337213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavatza&#xa0;K, Kostopoulou&#xa0;M, Nikolopoulos&#xa0;D et&#xa0;al (2021) Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a&#xa0;cohort of 220&#xa0;patients. Ann Rheum Dis 80:1175&#x2013;1182</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220438</ArticleId><ArticleId IdType="pubmed">34162597</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>